Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel, Active-Controlled Phase III Study on Metformin Combined With THR-1442 or Dapagliflozin in T2DM

NCT05159882 is registered in ClinicalTrials.gov with Newsoara Biopharma Co., Ltd. as lead sponsor.

NCT NCT05159882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel, Active-Controlled Phase III Study on Metformin Combined With THR-1442 or Dapagliflozin in T2DM
Lead sponsor
Newsoara Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
April 15, 2021
Completion date
September 30, 2022
Enrollment
390 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm